Amino Acid Therapy: A New Opportunity in Cancer Care
New Challenges in Cancer Treatment in Hong Kong
Free cancer support
New Challenges in Cancer Treatment in Hong Kong
Cancer has long been the leading cause of death in Hong Kong. According to the Hong Kong Cancer Registry, cancer has consistently ranked among the top ten causes of death in the city for many years. Although surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy have made significant progress, many patients still face substantial challenges: severe side effects, tumor recurrence and metastasis, and even drug resistance. These issues leave many patients feeling hopeless despite receiving standard treatments.
As a result, the medical community has sought new breakthroughs. One emerging approach that has received growing attention in recent years is Amino Acid Therapy. Unlike conventional treatments that directly aim to kill cancer cells, this therapy targets cancer cells’ “nutritional dependencies” by depriving or modulating specific amino acids, thereby inhibiting tumor growth and metastasis. For patients in Hong Kong, this represents a novel, lower-toxicity treatment option with the potential to enhance the effectiveness of existing therapies.
Why Traditional Treatments Are Insufficient
To understand the rationale behind amino acid therapy, it is essential to recognize the limitations of traditional treatments:
Severe Side Effects
Chemotherapy and radiotherapy can kill cancer cells but also attack normal cells, causing hair loss, nausea, immunosuppression, and bone marrow suppression. Many patients are forced to reduce doses or discontinue treatment due to their body’s inability to tolerate side effects.Tumor Drug Resistance
Cancer cells are highly adaptable. Even if initially sensitive to chemotherapy or targeted therapy, they often develop resistance over months or years, rendering treatments ineffective.Difficulties Controlling Metastasis and Recurrence
Many patients who have had their primary tumors surgically removed may still harbor cancer cells in the bloodstream or lymphatic system, leading to potential recurrence or metastasis in the future.Decline in Quality of Life
Long-term treatment side effects leave patients exhausted, affecting daily life, mental health, family, and work.
Hence, there is an urgent need for a therapy that complements traditional treatments while reducing toxicity and side effects — this is where amino acid therapy demonstrates its value.
Why Amino Acid Therapy?
Amino acid therapy addresses the blind spots of conventional treatment. Three key reasons explain why it is worth integrating into cancer care:
Targeting Cancer Cell Metabolic Vulnerabilities
One major difference between cancer cells and normal cells is the high dependency of cancer cells on certain amino acids. This “metabolic addiction” makes them a precise therapeutic target. By limiting or depriving specific amino acids, cancer cells can be selectively attacked without broadly harming normal cells.Enhancing Existing Therapies
Research has shown that amino acid therapy can improve the efficacy of chemotherapy, radiotherapy, and immunotherapy. For example, methionine restriction can increase tumor sensitivity to radiation, while arginine deprivation can boost immunotherapy response rates.Relatively Low Side Effects
Because amino acid therapy approaches cancer from a metabolic angle, its impact on normal cells is minimal. For patients in Hong Kong, this means extending life expectancy while maintaining a higher quality of life.
Core Principles of Amino Acid Therapy
Cancer cells require abundant nutrients to support uncontrolled growth. Unlike normal cells that can adjust metabolism under nutrient scarcity, cancer cells often rely on a single or limited set of amino acids to maintain malignancy. The three most notable amino acids are:
Asparagine – Critical for tumor metastasis
Arginine – Tumors unable to synthesize it rely on external supply
Methionine – Widely involved in DNA methylation and tumor metabolism
Understanding these metabolic vulnerabilities allows targeted strategies in amino acid therapy.
Asparagine Restriction — Key to Preventing Tumor Spread
Asparagine, a non-essential amino acid, is closely linked to tumor metastatic potential. Studies have shown that breast cancer cells exhibit significantly reduced metastatic ability under asparagine depletion.
Clinical applications include:
Using Asparaginase to degrade asparagine in the bloodstream.
Combining dietary and metabolic interventions to lower systemic asparagine levels.
Benefits:
Inhibits metastasis, reducing recurrence risk
Synergistic with chemotherapy
Highly targeted with limited impact on normal cells
For Hong Kong patients, this approach is especially suitable for high-metastatic-risk cancers such as breast and lung cancer.
Arginine Deprivation — Precisely Targeting Tumor Metabolic Defects
Many tumors, including liver cancer, melanoma, and sarcoma, cannot synthesize arginine and must rely on external supply. Arginine deprivation therapy deprives cancer cells of this essential nutrient.
Representative drug: PEG-ADI (polyethylene glycol–modified arginine deiminase), which effectively degrades circulating arginine.
Benefits:
Low toxicity and mild side effects
Clinical trials show significant efficacy in sarcoma and liver cancer
When combined with immunotherapy, it may enhance response rates
This therapy is particularly clinically valuable for liver cancer patients in Hong Kong.
Methionine Restriction — Enhancing Chemotherapy and Radiotherapy
Methionine, an essential amino acid, is more critical for cancer cells than for normal cells. Restricting methionine intake not only directly inhibits tumors but also increases their sensitivity to chemotherapy and radiotherapy.
Clinical application methods:
Implementing a low-methionine diet during treatment
Using pharmacological interventions to further reduce methionine availability to tumors
Benefits:
Applicable across multiple cancer types
Significant enhancement when combined with chemo- or radiotherapy
Patients can participate through diet, increasing a sense of control
Overall Benefits of Amino Acid Therapy
High selectivity: Targets metabolic vulnerabilities of cancer cells
Low side effects: Avoids widespread toxicity of traditional therapies
Complementary to existing therapies: Enhances chemotherapy, radiotherapy, and immunotherapy
Reduces resistance risk: Cancer cells are less likely to evolve resistance under nutrient restriction
Supports precision medicine: Patient selection possible through genetic or metabolic testing
For Hong Kong patients, this means treatment choices are no longer limited to “high toxicity” or “single-pathway” options but allow for pursuing both efficacy and quality of life.
Clinical Applications and International Progress
PEG-ADI: Entered multiple Phase II and III trials, especially for liver cancer and sarcoma
Asparagine restriction: Extended from leukemia to breast cancer, lung cancer, and other solid tumors
Methionine-restricted diet: Animal studies and preliminary clinical research show significant enhancement of chemo- and radiotherapy
Hong Kong’s healthcare system is gradually aligning with international standards, giving patients increased access to these metabolic therapies in the future.
Conclusion: A New Hope for Hong Kong Patients
Traditional therapies remain the cornerstone of cancer treatment, but side effects and drug resistance continue to challenge patients. Amino acid therapy, through its unique “metabolic deprivation” approach, complements traditional treatments.
Why use it? Because it can:
Specifically target cancer cells with low side effects
Enhance chemotherapy, radiotherapy, and immunotherapy effectiveness
Reduce resistance and recurrence risk
Provide patients with more treatment options and hope
For Hong Kong patients, amino acid therapy is not just a novel approach — it represents an opportunity to improve quality of life and extend survival. As research progresses, it may become a key component of future cancer care.
Want to know how to choose the most suitable adjuvant therapy for cancer?
Contact our professional team now
References
- Dillon, B. J., Prieto, V. G., Curley, S. A., Ensor, C. M., Holtsberg, F. W., Bomalaski, J. S., … & Clark, M. A. (2004). Incidence and distribution of argininosuccinate synthetase deficiency in human cancers. Cancer, 100(4), 826-833.
- Kremer, J. C., Prudner, B. C., Lange, S. E., Bean, G. R., Schultze, M. B., Brashears, C. B., … & Locasale, J. W. (2017). Arginine deprivation inhibits the Warburg effect and upregulates glutamine anaplerosis and serine biosynthesis in ASS1-deficient cancers. Cell Reports, 18(4), 991-1004.
- Maddocks, O. D. K., & Vousden, K. H. (2017). Metabolic regulation by p53. Cancer Metabolism, 5(1), 1-11.
- Newman, A. C., & Maddocks, O. D. K. (2017). One-carbon metabolism in cancer. British Journal of Cancer, 116(12), 1499–1504.
- Poillet-Perez, L., & White, E. (2019). Role of tumor and host autophagy in cancer metabolism. Genes & Development, 33(11-12), 610-619.
- Rabinovich, S., Adler, L., Yizhak, K., Sarver, A., Silberman, A., Agron, S., … & Erez, A. (2015). Diversion of aspartate in ASS1-deficient tumors fosters de novo pyrimidine synthesis. Nature, 527(7578), 379-383.
- Tang, X., Lin, C. C., Spasojevic, I., Iversen, E. S., Chi, J. T., & Marks, J. R. (2014). A joint analysis of metabolomics and genetics of breast cancer. Breast Cancer Research, 16(4), 415.